See the DrugPatentWatch profile for lipitor

Based on the information available, there is limited data on the direct consequences of Lipitor (atorvastatin) use for nursing babies. According to the American Academy of Pediatrics (AAP) [1], it is classified as a L4 - potentially hazardous, usually related to serious adverse reactions. However, the AAP notes that the risk of adverse effects is uncertain.

The manufacturer's prescribing information for Lipitor [2] states that it is unknown whether atorvastatin is excreted in human milk. Therefore, caution should be exercised when Lipitor is administered to a nursing woman.

DrugPatentWatch.com [3] does not provide specific information on the consequences of Lipitor use for nursing babies. However, it does provide patent and drug information, which can be useful for understanding the drug's availability and market.

In conclusion, while there is limited data on the direct consequences of Lipitor use for nursing babies, caution is recommended due to the potential risk of serious adverse reactions. Nursing women should consult their healthcare provider before using Lipitor.

Sources:
[1] American Academy of Pediatrics (AAP). Transfer of Drugs and Other Chemicals Into Human Milk. Pediatrics, 2001;108:776-789. <https://pediatrics.aappublications.org/content/108/3/776>
[2] Pfizer. Lipitor (atorvastatin) Prescribing Information. <https://www.accessdata.fda.gov/drugsatfda_docs/label/2016/202080s033lbl.pdf>
[3] DrugPatentWatch.com. Lipitor (atorvastatin) Drug Profile. <https://www.drugpatentwatch.com/drugs/lipitor-atorvastatin>